IPO registrations (S-1, F-1) · Registrants
AIM ImmunoTech Inc.
- SEC CIK
- 946644 · filings on EDGAR ↗
- Former names
- HEMISPHERX BIOPHARMA INC (1996–2019)
- Registration
- Form S-1, first filed 1996-07-26, last 2026-06-18; 20 initial registrations, 18 amendments
- Outcome
- Final prospectus filed 1998-02-25; declared effective 2006-08-07; withdrawal requested 2006-08-07
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 2117 SW HIGHWAY 484, Ocala, FL 32801
- EIN
- 52-0845822
- Ticker
- AIM (NYSE)
- EDGAR entity type
- operating
- Insiders and CEO pay
- AIM ImmunoTech Inc. on the corporate pages
On this site
- Business registration: AIM IMMUNOTECH INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: HEM PHARMACEUTICALS CORP. EXACT (EIN (EXACT, as the state registration reports it))
- Form 5500 plan sponsor: AIM IMMUNOTECH, INC. EXACT (EIN (EXACT))
- Form D issuer: AIM ImmunoTech Inc. EXACT (CIK (EXACT))
- Lobbying client: AIM IMMUNOTECH INC. Fuzzy (name and state)
- Lobbying client: AIM IMMUNOTECH INC. Fuzzy (name and state)
- SEC filer: AIM ImmunoTech Inc. EXACT (CIK (EXACT))
- Person page: Thomas K Equels Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer))
Filings 74
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 1996-07-26 | S-1 | S-1 (registration) | HEMISPHERX BIOPHARMA INC | 0000891092-96-000138 ↗ |
| 1996-09-11 | S-1/A | S-1/A (amendment) | HEMISPHERX BIOPHARMA INC | 0000891092-96-000172 ↗ |
| 1997-04-11 | S-1 | S-1 (registration) | HEMISPHERX BIOPHARMA INC | 0000891092-97-000109 ↗ |
| 1998-02-25 | 424B1 | 424B1 (final prospectus) | HEMISPHERX BIOPHARMA INC | 0000891092-98-000064 ↗ |
| 1999-04-13 | 424B1 | 424B1 (final prospectus) | HEMISPHERX BIOPHARMA INC | 0000891092-99-000183 ↗ |
| 1999-10-01 | 424B1 | 424B1 (final prospectus) | HEMISPHERX BIOPHARMA INC | 0000891092-99-000594 ↗ |
| 2000-03-06 | 424B1 | 424B1 (final prospectus) | HEMISPHERX BIOPHARMA INC | 0000891092-00-000161 ↗ |
| 2000-10-30 | 424B1 | 424B1 (final prospectus) | HEMISPHERX BIOPHARMA INC | 0000891092-00-000987 ↗ |
| 2003-09-09 | S-1 | S-1 (registration) | HEMISPHERX BIOPHARMA INC | 0000891092-03-002429 ↗ |
| 2003-10-09 | S-1/A | S-1/A (amendment) | HEMISPHERX BIOPHARMA INC | 0000891092-03-002721 ↗ |
| 2003-12-12 | S-1 | S-1 (registration) | HEMISPHERX BIOPHARMA INC | 0000891092-03-003645 ↗ |
| 2004-03-22 | S-1 | S-1 (registration) | HEMISPHERX BIOPHARMA INC | 0000891092-04-001352 ↗ |
| 2004-07-06 | S-1 | S-1 (registration) | HEMISPHERX BIOPHARMA INC | 0000891092-04-003115 ↗ |
| 2004-07-29 | S-1/A | S-1/A (amendment) | HEMISPHERX BIOPHARMA INC | 0000891092-04-003734 ↗ |
| 2006-07-31 | S-1 | S-1 (registration) | HEMISPHERX BIOPHARMA INC | 0001144204-06-030386 ↗ |
| 2006-08-04 | S-1/A | S-1/A (amendment) | HEMISPHERX BIOPHARMA INC | 0001144204-06-031061 ↗ |
| 2006-08-07 | RW | RW (withdrawal request) | HEMISPHERX BIOPHARMA INC | 0001144204-06-031282 ↗ |
| 2006-08-07 | S-1/A | S-1/A (amendment) | HEMISPHERX BIOPHARMA INC | 0001144204-06-031293 ↗ |
| 2006-08-07 | EFFECT | EFFECT (declared effective) | HEMISPHERX BIOPHARMA INC | 9999999995-06-001093 ↗ |
| 2007-05-16 | EFFECT | EFFECT (declared effective) | HEMISPHERX BIOPHARMA INC | 9999999995-07-001973 ↗ |
| 2008-05-01 | EFFECT | EFFECT (declared effective) | HEMISPHERX BIOPHARMA INC | 9999999995-08-001385 ↗ |
| 2008-06-27 | EFFECT | EFFECT (declared effective) | HEMISPHERX BIOPHARMA INC | 9999999995-08-002051 ↗ |
| 2008-08-12 | EFFECT | EFFECT (declared effective) | HEMISPHERX BIOPHARMA INC | 9999999995-08-002549 ↗ |
| 2009-04-09 | S-1 | S-1 (registration) | HEMISPHERX BIOPHARMA INC | 0000946644-09-000009 ↗ |
| 2009-04-23 | RW | RW (withdrawal request) | HEMISPHERX BIOPHARMA INC | 0000946644-09-000010 ↗ |
| 2009-04-24 | EFFECT | EFFECT (declared effective) | HEMISPHERX BIOPHARMA INC | 9999999995-09-001045 ↗ |
| 2009-06-22 | EFFECT | EFFECT (declared effective) | HEMISPHERX BIOPHARMA INC | 9999999995-09-001723 ↗ |
| 2009-07-01 | EFFECT | EFFECT (declared effective) | HEMISPHERX BIOPHARMA INC | 9999999995-09-001828 ↗ |
| 2012-07-02 | EFFECT | EFFECT (declared effective) | HEMISPHERX BIOPHARMA INC | 9999999995-12-002025 ↗ |
| 2015-08-04 | EFFECT | EFFECT (declared effective) | HEMISPHERX BIOPHARMA INC | 9999999995-15-002170 ↗ |
| 2017-05-04 | S-1 | S-1 (registration) | HEMISPHERX BIOPHARMA INC | 0001493152-17-004754 ↗ |
| 2017-05-19 | S-1/A | S-1/A (amendment) | HEMISPHERX BIOPHARMA INC | 0001493152-17-005636 ↗ |
| 2017-05-23 | EFFECT | EFFECT (declared effective) | HEMISPHERX BIOPHARMA INC | 9999999995-17-001366 ↗ |
| 2017-09-29 | S-1 | S-1 (registration) | HEMISPHERX BIOPHARMA INC | 0001493152-17-011090 ↗ |
| 2017-10-12 | EFFECT | EFFECT (declared effective) | HEMISPHERX BIOPHARMA INC | 9999999995-17-002672 ↗ |
| 2018-07-02 | S-1 | S-1 (registration) | HEMISPHERX BIOPHARMA INC | 0001493152-18-009591 ↗ |
| 2018-07-20 | S-1/A | S-1/A (amendment) | HEMISPHERX BIOPHARMA INC | 0001493152-18-010275 ↗ |
| 2018-08-03 | EFFECT | EFFECT (declared effective) | HEMISPHERX BIOPHARMA INC | 9999999995-18-002005 ↗ |
| 2018-08-03 | EFFECT | EFFECT (declared effective) | HEMISPHERX BIOPHARMA INC | 9999999995-18-002006 ↗ |
| 2018-12-27 | S-1 | S-1 (registration) | HEMISPHERX BIOPHARMA INC | 0001493152-18-018009 ↗ |
| 2019-02-06 | S-1/A | S-1/A (amendment) | HEMISPHERX BIOPHARMA INC | 0001493152-19-001474 ↗ |
| 2019-02-14 | 424B4 | 424B4 (final prospectus) | HEMISPHERX BIOPHARMA INC | 0001493152-19-002134 ↗ |
| 2019-02-14 | EFFECT | EFFECT (declared effective) | HEMISPHERX BIOPHARMA INC | 9999999995-19-000268 ↗ |
| 2019-09-06 | S-1 | S-1 (registration) | AIM ImmunoTech Inc. | 0001493152-19-013823 ↗ |
| 2019-09-24 | S-1/A | S-1/A (amendment) | AIM ImmunoTech Inc. | 0001493152-19-014454 ↗ |
| 2019-09-24 | S-1/A | S-1/A (amendment) | AIM ImmunoTech Inc. | 0001493152-19-014486 ↗ |
| 2019-09-25 | S-1/A | S-1/A (amendment) | AIM ImmunoTech Inc. | 0001493152-19-014528 ↗ |
| 2019-09-25 | EFFECT | EFFECT (declared effective) | AIM ImmunoTech Inc. | 9999999995-19-002175 ↗ |
| 2019-09-26 | 424B4 | 424B4 (final prospectus) | AIM ImmunoTech Inc. | 0001493152-19-014625 ↗ |
| 2022-01-21 | EFFECT | EFFECT (declared effective) | AIM ImmunoTech Inc. | 9999999995-22-000188 ↗ |
| 2022-02-04 | EFFECT | EFFECT (declared effective) | AIM ImmunoTech Inc. | 9999999995-22-000346 ↗ |
| 2024-04-19 | S-1 | S-1 (registration) | AIM ImmunoTech Inc. | 0001493152-24-015368 ↗ |
| 2024-05-01 | EFFECT | EFFECT (declared effective) | AIM ImmunoTech Inc. | 9999999995-24-001329 ↗ |
| 2024-07-11 | S-1 | S-1 (registration) | AIM ImmunoTech Inc. | 0001493152-24-027002 ↗ |
| 2024-07-25 | EFFECT | EFFECT (declared effective) | AIM ImmunoTech Inc. | 9999999995-24-002279 ↗ |
| 2024-11-15 | S-1 | S-1 (registration) | AIM ImmunoTech Inc. | 0001493152-24-046305 ↗ |
| 2024-12-04 | EFFECT | EFFECT (declared effective) | AIM ImmunoTech Inc. | 9999999995-24-003662 ↗ |
| 2025-01-23 | S-1 | S-1 (registration) | AIM ImmunoTech Inc. | 0001493152-25-003444 ↗ |
| 2025-02-03 | S-1/A | S-1/A (amendment) | AIM ImmunoTech Inc. | 0001493152-25-004609 ↗ |
| 2025-02-07 | S-1/A | S-1/A (amendment) | AIM ImmunoTech Inc. | 0001493152-25-005312 ↗ |
| 2025-07-03 | EFFECT | EFFECT (declared effective) | AIM ImmunoTech Inc. | 9999999995-25-002161 ↗ |
| 2025-07-15 | S-1/A | S-1/A (amendment) | AIM ImmunoTech Inc. | 0001493152-25-011234 ↗ |
| 2025-07-22 | S-1/A | S-1/A (amendment) | AIM ImmunoTech Inc. | 0001641172-25-020534 ↗ |
| 2025-07-28 | EFFECT | EFFECT (declared effective) | AIM ImmunoTech Inc. | 9999999995-25-002368 ↗ |
| 2025-12-12 | S-1 | S-1 (registration) | AIM ImmunoTech Inc. | 0001493152-25-027319 ↗ |
| 2026-01-23 | S-1/A | S-1/A (amendment) | AIM ImmunoTech Inc. | 0001493152-26-003343 ↗ |
| 2026-01-29 | S-1/A | S-1/A (amendment) | AIM ImmunoTech Inc. | 0001493152-26-004238 ↗ |
| 2026-02-10 | S-1/A | S-1/A (amendment) | AIM ImmunoTech Inc. | 0001493152-26-005975 ↗ |
| 2026-02-10 | EFFECT | EFFECT (declared effective) | AIM ImmunoTech Inc. | 9999999995-26-000511 ↗ |
| 2026-02-17 | 424B4 | 424B4 (final prospectus) | AIM ImmunoTech Inc. | 0001493152-26-006944 ↗ |
| 2026-06-08 | S-1 | S-1 (registration) | AIM ImmunoTech Inc. | 0001493152-26-027714 ↗ |
| 2026-06-16 | EFFECT | EFFECT (declared effective) | AIM ImmunoTech Inc. | 9999999995-26-002022 ↗ |
| 2026-06-18 | S-1 | S-1 (registration) | AIM ImmunoTech Inc. | 0001493152-26-029193 ↗ |
| 2026-06-23 | EFFECT | EFFECT (declared effective) | AIM ImmunoTech Inc. | 9999999995-26-002094 ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| CARTER WILLIAM A | Director,Officer; Director,Officer,TenPercentOwner | CEO; Chief Executive Officer; COO | 45 | 2006–2015 | |
| SPENCE STEVEN D | Director | 5 | 2006–2007 | ||
| PIANI RICHARD | Director | 14 | 2006–2012 | ||
| Bonelli Anthony | Officer | COO; President & COO; President, COO | 5 | 2006–2007 | |
| ETHERIDGE RANSOM | Director,Officer | Secretary; Secretary and General Counsel; Secretary & General Conunsel; Secretary & General Counsel | 10 | 2007–2008 | |
| MITCHELL WILLIAM M | Director | 74 | 2007–2025 | ||
| PETERSON ROBERT E | Officer | CFO; Chief Financial Officer | 5 | 2007–2008 | |
| STRAYER DAVID R | Officer; Other | Chief Science/Medical Officer; Chief Science/MedicalOfficer; Medical Director | 37 | 2007–2019 | |
| KIANI IRAJ EGHBAL | Director | 21 | 2007–2016 | ||
| Equels Thomas K | Director; Director,Officer; Officer | CEO; CEO,Pres,Exec Vice Chairman; CEO & President; CEO / President; CEO, President; CEO,President; CFO, Pres.,Sec., Vice Chairman; CFO, Vice Chairman, Secretary; CFO,Vice Chairman,Secretary; Exec. Vice Chairman/CEO/Pres.; Exec.Vice Chairman/CEO/Pres.; Exec Vice Chairman of Board; Exec Vice Chairman, Secretary; Exec Vice Chairman,Secretary; General Counsel; Vice Chairman of Board | 112 | 2008–2026 | person page Fuzzy |
| Bernhardt Charles Thomas III | Officer | CFO; Chief Financial Officer | 9 | 2009–2011 | |
| Springate Wayne S. | Officer; Other | Senior VP of Operations; Sr VP of Operations; Sr. VP of Operations; SR VP of Operations; Vice President of Operations; VP of Operations | 41 | 2009–2019 | |
| Dickey Robert IV | Officer | Chief Financial Officer; Senior Vice President | 4 | 2009–2022 | |
| Lander Russel J | Officer | VP of Process/QualityAssurance | 3 | 2011 | |
| Cavalli Ralph Christopher | Officer | VP, Quality Control | 2 | 2011–2012 | |
| RODINO III PETER W. | Director; Officer | COO, Secretary, Gen. Counsel; COO,Secretary,Gen Counsel; Dir Govt Relations/Sectry; Exec Dir Govt Relations/Secrty; Exec Dir Govt Relations/Sectry | 48 | 2013–2025 | |
| Pascale Adam | Officer | CEO; CFO; Chief Accounting Officer | 33 | 2014–2019 | |
| Appelrouth Stewart | Director | 51 | 2017–2025 | ||
| LINTAL ELLEN M | Officer; Other | CFO; Chief Financial Officer | 10 | 2019–2023 | |
| BRYAN NANCY | Director | 10 | 2023–2025 | ||
| KELLNER TED D | Director | 3 | 2024–2025 | ||
| CHEMEROW DAVID I. | Director | 6 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-02-20 | AIM ImmunoTech Inc. | Biotechnology | $3,301,250 | $3,301,250 | 1 | 2 |
| 2018-04-25 | HEMISPHERX BIOPHARMA INC | Pharmaceuticals | $25,740 | $25,740 | 3 | 1 |
| 2017-02-13 | HEMISPHERX BIOPHARMA INC | Pharmaceuticals | $18,182 | $18,182 | 4 | 1 |
| 2016-09-02 | HEMISPHERX BIOPHARMA INC | Pharmaceuticals | $33,334 | $33,334 | 3 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.